Control of clofibrate toxicity in uremic hypertriglyceridemia.

@article{Goldberg1977ControlOC,
  title={Control of clofibrate toxicity in uremic hypertriglyceridemia.},
  author={Andrew P. Goldberg and Donald J. Sherrard and Linda B. Haas and John D. Brunzell},
  journal={Clinical pharmacology and therapeutics},
  year={1977},
  volume={21 3},
  pages={317-25}
}
A daily dose of 1.5 to 2.0 gm of clofibrate lowers serum triglyceride (TG) levels in patients with normal renal function but causes muscle toxicity and elevated creatine phosphokinase (CPK) levels in patients with long-term renal failure. Plasma clofibrate disappearance is prolonged as much as seven times normal in severely uremic patients. A marked reduction in the standard 14 gm/wk clofibrate dose to a total dose of 1.0 to 1.5 gm/wk effectively lowered serum TG levels (--28%, p less than 0.02… CONTINUE READING